BNP Paribas Asset Management
NRIX icon

BNP Paribas Asset Management’s Nurix Therapeutics NRIX Stock Holding History

BNP Paribas Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.2K Sell
790
-745
-49% -$12.7K ﹤0.01% 2062
2026
Q1 		$23.8K Buy
+1,535
New +$25.5K ﹤0.01% 1978

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BNP Paribas Asset Management's NRIX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Nurix Therapeutics (NRIX) stake by 49% in Q2 2026, selling an estimated $12.7K and leaving 790 shares worth $19.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2062.

BNP Paribas Asset Management first reported a position in NRIX in Q1 2026 and has held it in 2 quarters since. The position peaked at $23.8K in Q1 2026. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • BNP Paribas Asset Management held 790 shares of Nurix Therapeutics worth $19.2K as of Q2 2026.
  • BNP Paribas Asset Management sold 745 Nurix Therapeutics shares in Q2 2026, an estimated $12.7K.
  • Nurix Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2062 holding.
  • BNP Paribas Asset Management first reported a position in Nurix Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • BNP Paribas Asset Management's Nurix Therapeutics position peaked at $23.8K in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.